Skip to main content

A yeast expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates.

Publication ,  Journal Article
Pino, M; Abid, T; Pereira Ribeiro, S; Edara, VV; Floyd, K; Smith, JC; Latif, MB; Pacheco-Sanchez, G; Dutta, D; Wang, S; Gumber, S; Cohen, J ...
Published in: Sci Immunol
July 15, 2021

Ongoing SARS-CoV-2 vaccine development is focused on identifying stable, cost-effective, and accessible candidates for global use, specifically in low and middle-income countries. Here, we report the efficacy of a rapidly scalable, novel yeast expressed SARS-CoV-2 specific receptor-binding domain (RBD) based vaccine in rhesus macaques. We formulated the RBD immunogen in alum, a licensed and an emerging alum adsorbed TLR-7/8 targeted, 3M-052-alum adjuvants. The RBD+3M-052-alum adjuvanted vaccine promoted better RBD binding and effector antibodies, higher CoV-2 neutralizing antibodies, improved Th1 biased CD4+T cell reactions, and increased CD8+ T cell responses when compared to the alum-alone adjuvanted vaccine. RBD+3M-052-alum induced a significant reduction of SARS-CoV-2 virus in respiratory tract upon challenge, accompanied by reduced lung inflammation when compared with unvaccinated controls. Anti-RBD antibody responses in vaccinated animals inversely correlated with viral load in nasal secretions and BAL. RBD+3M-052-alum blocked a post SARS-CoV-2 challenge increase in CD14+CD16++ intermediate blood monocytes, and Fractalkine, MCP-1, and TRAIL in the plasma. Decreased plasma analytes and intermediate monocyte frequencies correlated with reduced nasal and BAL viral loads. Lastly, RBD-specific plasma cells accumulated in the draining lymph nodes and not in the bone marrow, contrary to previous findings. Together, these data show that a yeast expressed, RBD-based vaccine+3M-052-alum provides robust immune responses and protection against SARS-CoV-2, making it a strong and scalable vaccine candidate.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Sci Immunol

DOI

EISSN

2470-9468

Publication Date

July 15, 2021

Volume

6

Issue

61

Location

United States

Related Subject Headings

  • Viral Load
  • Spike Glycoprotein, Coronavirus
  • Saccharomycetales
  • SARS-CoV-2
  • Protein Domains
  • Protein Binding
  • Male
  • Macaca mulatta
  • Lung
  • Immunoglobulin G
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Pino, M., Abid, T., Pereira Ribeiro, S., Edara, V. V., Floyd, K., Smith, J. C., … Kasturi, S. P. (2021). A yeast expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates. Sci Immunol, 6(61). https://doi.org/10.1126/sciimmunol.abh3634
Pino, Maria, Talha Abid, Susan Pereira Ribeiro, Venkata Viswanadh Edara, Katharine Floyd, Justin C. Smith, Muhammad Bilal Latif, et al. “A yeast expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates.Sci Immunol 6, no. 61 (July 15, 2021). https://doi.org/10.1126/sciimmunol.abh3634.
Pino M, Abid T, Pereira Ribeiro S, Edara VV, Floyd K, Smith JC, et al. A yeast expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates. Sci Immunol. 2021 Jul 15;6(61).
Pino, Maria, et al. “A yeast expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates.Sci Immunol, vol. 6, no. 61, July 2021. Pubmed, doi:10.1126/sciimmunol.abh3634.
Pino M, Abid T, Pereira Ribeiro S, Edara VV, Floyd K, Smith JC, Latif MB, Pacheco-Sanchez G, Dutta D, Wang S, Gumber S, Kirejczyk S, Cohen J, Stammen RL, Jean SM, Wood JS, Connor-Stroud F, Pollet J, Chen W-H, Wei J, Zhan B, Lee J, Liu Z, Strych U, Shenvi N, Easley K, Weiskopf D, Sette A, Pollara J, Mielke D, Gao H, Eisel N, LaBranche CC, Shen X, Ferrari G, Tomaras GD, Montefiori DC, Sekaly RP, Vanderford TH, Tomai MA, Fox CB, Suthar MS, Kozlowski PA, Hotez PJ, Paiardini M, Bottazzi ME, Kasturi SP. A yeast expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates. Sci Immunol. 2021 Jul 15;6(61).

Published In

Sci Immunol

DOI

EISSN

2470-9468

Publication Date

July 15, 2021

Volume

6

Issue

61

Location

United States

Related Subject Headings

  • Viral Load
  • Spike Glycoprotein, Coronavirus
  • Saccharomycetales
  • SARS-CoV-2
  • Protein Domains
  • Protein Binding
  • Male
  • Macaca mulatta
  • Lung
  • Immunoglobulin G